# US 2023/0265458 A1 · Gene therapy vector with minimizing recombination, recombinant retrovirus comprising the vector, and pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265458 A1
- Document ID: US20230265458A1
- Status: Published application
- Kind: A1
- Application number: 18/185,656
- Filed: 2023-03-17
- Published: 2023-08-24
- Earliest claimed: 2020-09-18
- Assignees: ArtiCure, Inc.
- Applicants: Articure Inc.
- Inventors: Yeon-Soo KIM; Moonkyung KANG; Soojin KIM
- Web page: https://patentgrep.com/patent/US20230265458A1

## CPC

- C12N 15/86: Viral vectors
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61P 35/00: Antineoplastic agents
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 9/1211: {Thymidine kinase (2.7.1.21)}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12Y 207/01021: Thymidine kinase (2.7.1.21)
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C12Y 305/04001: Cytosine deaminase (3.5.4.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Disclosed is a gene therapy vector in which the occurrence of recombination is minimized. In order to minimize the occurrence of recombination, which is a major problem in the production and infection of a retroviral vector virus that continuously expresses a therapeutic gene during virus replication, a cleaved MCMV promoter was prepared by cutting the MCMV promoter on the basis of a repeat sequence, and the cleaved MCMV promoter was introduced to prepare a vector. It was confirmed that the vector having the cleaved MCMV promoter incorporated therein does not cause recombinations even after being incubated multiple times, and shows a continuous expression of the therapeutic protein, and in cells transfected with the virus containing the vector, cell death effectively occurs when a prodrug is administered thereto. Accordingly, the vector with minimized recombination occurrence of the present invention can be advantageously used for the treatment of cancer.

## Claims

### Claim 1

A replicating-retrovirus vector with minimized recombination occurrence, comprising a first recombinant expression vector containing a Gag-Pol gene, a sEF1α (short elongation factor 1α) promoter or a MCMV (murine cytomegalovirus) promoter, and a first therapeutic gene; and a second recombinant expression vector containing an Env gene of a virus, an MCMV promoter and a second therapeutic gene, wherein the MCMV promoter is a cleaved MCMV promoter selected from the group consisting of polynucleotides having the nucleotide sequences represented by SEQ. ID. NO: 4, NO: 5, NO: 6 and NO: 7.

### Claim 2 (depends on 1)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 1, wherein the Gag-Pol gene is a Gag-Pol gene of Gibbon ape Leukemia virus (GaLV) or amphotropic murine leukemia virus (MuLV).

### Claim 3 (depends on 1)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 1, wherein the MCMV promoter is a polynucleotide having the nucleotide sequence represented by SEQ. ID. NO: 3.

### Claim 4 (depends on 1)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 1, wherein the sEF1α promoter is a polynucleotide having the nucleotide sequence represented by SEQ. ID. NO: 18.

### Claim 5 (depends on 1)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 1, wherein the virus Env gene is any one derived from the group consisting of Gibbon ape Leukemia virus (GaLV), amphotropic murine leukemia virus (MuLV), xenotropic murine leukemia virus (xenotropic MuLV), feline endogenous retrovirus (RD114), vesicular stomatitis virus (VSV) and measles virus (MV) Env genes.

### Claim 6 (depends on 1)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 1, wherein the first therapeutic gene or the second therapeutic gene is any one selected from the group consisting of a suicide gene, a cytokine gene, and a cancer antigen gene.

### Claim 7 (depends on 6)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 6, wherein the suicide gene is a thymidine kinase (TK) gene or a yeast cytosine deaminase (yCD) gene.

### Claim 8 (depends on 6)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 6, wherein the cytokine gene is a granulocyte macrophage colony-stimulating factor (GM-CSF).

### Claim 9 (depends on 6)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 6, wherein the cancer antigen gene is human CD19 (Cluster of Differentiation 19), CEA (Carcinoembryonic Antigen), or HER2 (human epidermal growth factor receptor 2).

### Claim 10 (depends on 9)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 9, wherein the human CD19 gene is a polynucleotide having the nucleotide sequence represented by SEQ. ID. NO: 43.

### Claim 11 (depends on 9)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 9, wherein the truncated human CD19 gene is a polynucleotide having the nucleotide sequence represented by SEQ. ID. NO: 53.

### Claim 12 (depends on 7)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 7, wherein the thymidine kinase or yeast cytosine deaminase gene activates a precursor drug.

### Claim 13 (depends on 12)

The replicating-retrovirus vector with minimized recombination occurrence according to claim 12, wherein the precursor drug is at least one selected from the group consisting of ganciclovir (GCV) and 5-fluorocytosine (5-FC).

### Claim 14 (depends on 1)

A recombinant retrovirus comprising the vector of claim 1.

### Claim 15 (depends on 14)

A cell transfected or transduced with the recombinant retrovirus of claim 14.

### Claim 16 (depends on 14)

A pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus of claim 14 as an active ingredient.

### Claim 17 (depends on 15)

A pharmaceutical composition for preventing or treating cancer comprising the cell transfected or transduced with the recombinant retrovirus of claim 15.

### Claim 18 (depends on 16)

The pharmaceutical composition for preventing or treating cancer according to claim 16, wherein the cancer is selected from the group consisting of mucinous cell carcinoma, round cell carcinoma, locally advanced tumor, metastatic cancer, Ewing's sarcoma, cancer metastasis, lymphoid metastasis, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, multiple myeloma, acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, hairy cell leukemia, effluent lymphoma (celiac lymphoma), thymic lymphoma lung cancer, small cell lung carcinoma, cutaneous T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, adrenocortical cancer, ACTH-producing tumor, non-small cell lung cancer, breast cancer, small cell carcinoma, ductal carcinoma, stomach cancer, colon cancer, colorectal cancer, polyps associated with colorectal neoplasia, pancreatic cancer, liver cancer, bladder cancer, primary superficial bladder tumor, invasive metastatic cell bladder carcinoma of the bladder, muscle invasive bladder cancer, prostate cancer, colorectal cancer, kidney cancer, liver cancer, esophageal cancer, ovarian carcinoma, cervical cancer, endometrial cancer, choriocarcinoma, ovarian cancer, primary peritoneal epithelial neoplasia, cervical carcinoma, vaginal cancer, vulvar cancer, uterine cancer, follicular solid tumor, testicular cancer, penile cancer, renal cell carcinoma, brain cancer, head and neck cancer, neuroblastoma, brainstem glioma, glioma, metastatic tumor cell infiltration in the central nervous system, osteoma, osteosarcoma, malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, thyroid cancer, retinoblastoma, neuroblastoma, mesothelioma, Wilms' tumor, gallbladder cancer, trophoblastic tumor, hemangiopericytoma and Kaposi's sarcoma.

### Claim 19 (depends on 14)

A gene delivery composition for treating cancer comprising the recombinant retrovirus of claim 14.

### Claim 20

A method for preparing a replicating-retrovirus vector with minimized recombination occurrence comprising the following steps:
1) a step of preparing a first recombinant expression vector containing a Gag-Pol gene of MuLV (Murine Leukemia virus), a sEF1α promoter or an MCMV promoter, and a first therapeutic gene; and
2) a step of preparing a second recombinant expression vector containing an Env gene of a virus, an MCMV promoter, and a second therapeutic gene, wherein the MCMV promoter is selected from the group consisting of polynucleotides having the nucleotide sequences represented by SEQ. ID. NO: 4, NO: 5, NO: 6 and NO: 7.
